Tranexamic Acid for Anaemia Trial

NCT06519422 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4000

Last updated 2026-08-17

No results posted yet for this study

Summary

Anaemia is when the body does not have enough healthy red blood cells to carry oxygen. It is common in women because they lose blood every month during their periods. Anaemia can womwn make feel tired, weak, dizzy and out of breath. It can also make it harder to study, work or look after their family. If woman become pregnant with anaemia, it can cause problems for both mother and baby, such as early birth or heavy bleeding when giving birth. It is best to treat anaemia in young women well before they get pregnant. Doctors treat anaemia with iron and vitamins. But some people get side effects when taking iron tablets and so they stop taking them. Tranexamic acid (TXA) is a medicine used to treat heavy periods. The investigators of this study would like to find out if taking TXA with the usual iron and vitamin supplements is better at treating anaemia than taking iron and vitamin supplements alone. (Lay Summary)

Conditions

  • Anaemia

Interventions

DRUG

Tranexamic Acid 500 MG

Tablets

DRUG

Placebo

Tablets

Sponsors & Collaborators

  • University of Dar es Salaam, Tanzania (Mbeya College of Health and Allied Sciences)

    collaborator UNKNOWN
  • Coefficient Giving (Formerly Open Philanthropy)

    collaborator UNKNOWN
  • Versailles Saint-Quentin-en-Yvelines University

    collaborator OTHER
  • Shifa Tameer-e-Millat University

    collaborator OTHER
  • University College Hospital, Ibadan

    collaborator OTHER
  • The Jon Moulton Charity Trust

    collaborator UNKNOWN
  • University of Edinburgh

    collaborator OTHER
  • London School of Hygiene and Tropical Medicine

    lead OTHER

Principal Investigators

  • Professor Ian Roberts · London School of Hygiene and Tropical Medicine (Clinical Trials Unit)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-10
Primary Completion
2028-08-31
Completion
2028-09-30

Countries

  • Nigeria
  • Pakistan
  • Tanzania

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06519422 on ClinicalTrials.gov